Search This Blog

Thursday, August 13, 2026

Capricor pivots deramocel to skeletal muscle, upper limb function after negative cardio AdComm vote

 

Capricor pivots deramocel strategy to skeletal muscle, refocusing on upper limb function after negative cardiomyopathy AdComm vote

  • Fiscal Q2 2026 non-GAAP EPS was $-0.70 (-23% YoY), missing analyst EPS estimates
  • Fiscal Q2 2026 revenue was $0, beating analyst revenue estimates
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)